Head to Head Analysis: InflaRx (NASDAQ:IFRX) versus PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Earnings and Valuation

This table compares PDS Biotechnology and InflaRx”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$42.94 million	($1.36)	-2.29
InflaRx	$70,000.00	1,320.59	-$46.18 million	($0.89)	-1.76

PDS Biotechnology has higher earnings, but lower revenue than InflaRx. PDS Biotechnology is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

PDS Biotechnology has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Institutional and Insider Ownership

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 10.0% of PDS Biotechnology shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for PDS Biotechnology and InflaRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	0	0	4	1	3.20
InflaRx	0	0	1	1	3.50

PDS Biotechnology presently has a consensus target price of $14.25, suggesting a potential upside of 356.73%. InflaRx has a consensus target price of $13.50, suggesting a potential upside of 759.87%. Given InflaRx’s stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than PDS Biotechnology.

Profitability

This table compares PDS Biotechnology and InflaRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-137.06%	-66.12%
InflaRx	-44,046.09%	-47.03%	-41.56%

Summary

InflaRx beats PDS Biotechnology on 8 of the 12 factors compared between the two stocks.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.